Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 19, 2015 08:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Interim Phase 2 Data for Lead Clinical Candidate CA4P (fosbretabulin) in Neuroendocrine Tumors

-- Biomarker results in first nine subjects add to CA4P evidence of activity -- -- Full results are expected in the second half of 2016 -- SOUTH SAN FRANCISCO, Calif., Oct. 19, 2015 (GLOBE...
October 16, 2015 12:30 ET | Source: Mateon Therapeutics

OXiGENE to Present at the 14th Annual BIO Investor Forum

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, today announced that it...
September 29, 2015 16:05 ET | Source: Mateon Therapeutics

OXiGENE Announces Plans to Advance CA4P (Fosbretabulin) in Two Late-Stage Clinical Trials

Company plans to conduct two new phase 2/3 randomized studies in ovarian cancer and glioblastoma multiforme Both studies combine CA4P with an approved anti-VEGF treatment with a complementary...
August 04, 2015 16:00 ET | Source: Mateon Therapeutics

OXiGENE Reports Second Quarter 2015 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 4, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for treatment of cancer, today reported financial...
July 28, 2015 09:00 ET | Source: Mateon Therapeutics

OXiGENE to Host Second Quarter Financial Results Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for treatment of cancer, today announced that the...
July 20, 2015 16:00 ET | Source: Mateon Therapeutics

OXiGENE Appoints Matthew M. Loar as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., July 20, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for treatment of cancer, today announced that Matthew...
June 01, 2015 08:30 ET | Source: Mateon Therapeutics

OXiGENE Receives Guidance from FDA Supporting Phase 3 Trial of Fosbretabulin/Bevacizumab Combination in Platinum-Resistant Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., June 1, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for the treatment of cancer, today provided an update...
May 26, 2015 16:05 ET | Source: Mateon Therapeutics

OXiGENE Announces Issuance of U.S. Patent for OXi4503 in Acute Myeloid Leukemia

SOUTH SAN FRANCISCO, Calif., May 26, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for the treatment of cancer, today announced that the...
May 12, 2015 16:00 ET | Source: Mateon Therapeutics

OXiGENE Appoints Bill Schwieterman, M.D., as President and Chief Executive Officer

SOUTH SAN FRANCISCO, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced the...
April 30, 2015 16:00 ET | Source: Mateon Therapeutics

OXiGENE Reports First Quarter 2015 Financial Results

SOUTH SAN FRANCISCO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported...